- Home
- TSVT vs PSTX Comparison
TSVT vs PSTX Comparison
Compare TSVT & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- PSTX
- Stock Information
- Founded
- TSVT 2021
- PSTX 2014
- Country
- TSVT United States
- PSTX United States
- Employees
- TSVT N/A
- PSTX N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSVT Health Care
- PSTX Health Care
- Exchange
- TSVT Nasdaq
- PSTX Nasdaq
- Market Cap
- TSVT 253.9M
- PSTX 274.9M
- IPO Year
- TSVT N/A
- PSTX 2020
- Fundamental
- Price
- TSVT $4.83
- PSTX $2.61
- Analyst Decision
- TSVT Buy
- PSTX Strong Buy
- Analyst Count
- TSVT 6
- PSTX 3
- Target Price
- TSVT $10.40
- PSTX $14.67
- AVG Volume (30 Days)
- TSVT 341.4K
- PSTX 545.8K
- Earning Date
- TSVT 11-12-2024
- PSTX 11-07-2024
- Dividend Yield
- TSVT N/A
- PSTX N/A
- EPS Growth
- TSVT N/A
- PSTX N/A
- EPS
- TSVT N/A
- PSTX N/A
- Revenue
- TSVT $44,120,000.00
- PSTX $88,462,000.00
- Revenue This Year
- TSVT N/A
- PSTX $36.53
- Revenue Next Year
- TSVT $22.42
- PSTX N/A
- P/E Ratio
- TSVT N/A
- PSTX N/A
- Revenue Growth
- TSVT N/A
- PSTX N/A
- 52 Week Low
- TSVT $1.54
- PSTX $1.83
- 52 Week High
- TSVT $6.40
- PSTX $4.27
- Technical
- Relative Strength Index (RSI)
- TSVT 52.75
- PSTX 38.31
- Support Level
- TSVT $4.44
- PSTX $2.50
- Resistance Level
- TSVT $4.83
- PSTX $3.92
- Average True Range (ATR)
- TSVT 0.33
- PSTX 0.25
- MACD
- TSVT -0.00
- PSTX -0.07
- Stochastic Oscillator
- TSVT 56.86
- PSTX 7.74
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.